BridgeMD
New treatment option for Myocardial Infarction (MI)
Official title Timing of Coronary Angiography in NSTEMI Complicated by Acute HF
ClinicalTrials.gov ID: NCT07002164
What this study is testing
- What it's testing
- Study objectives: To determine the optimal timing of coronary angiography (CAG) in patients with non-ST-segment elevation myocardial infarction (NSTEMI) complicated by acute decompensated heart failure (AHF). The primary objective of this trial is to test the hypothesis that immediate CAG ≤2 hours after establishment of NSTEMI diagnosis would result in a significant reduction in primary composite outcome of death from any cause, non-fatal myocardial infarction (MI), or hospitalization for heart failure (HF) at 12 months after randomization as compared with delayed CAG after stabilization.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 19 and older
You may be able to join if
- Age ≥19 years
- Non-ST-segment elevation myocardial infarction
- New-onset or worsening of dyspnea (New York Heart Association class ≥2)
- Pulmonary congestion
- Patient's or guardian's consent after understanding the study
You likely can't join if
- Cardiogenic shock at initial presentation
- ST-segment elevation myocardial infarction
- ST-segment elevation ≥0.1 mV in at least 2 contiguous leads, or
- New onset left bundle branch block
- Posterior wall myocardial infarction
- Refractory angina
See the full eligibility criteria
- Age ≥19 years
- Non-ST-segment elevation myocardial infarction
- New-onset or worsening of dyspnea (New York Heart Association class ≥2)
- Pulmonary congestion
- Patient's or guardian's consent after understanding the study
- Cardiogenic shock at initial presentation
- ST-segment elevation myocardial infarction
- ST-segment elevation ≥0.1 mV in at least 2 contiguous leads, or
- New onset left bundle branch block
- Posterior wall myocardial infarction
- Refractory angina
- Life threatening ventricular arrhythmias
- Life expectancy \<1 year
- Apparently non-ischemic cause of HF
- Pregnancy and lactation
- History of coronary artery bypass grafting (CABG), or planned CABG
- Patient's refusal to participate in study
The study team makes the final eligibility decision.
Where it's taking place
- Changwon, South Korea
- Daegu, South Korea
- Daejeon, South Korea
- Gwangju, South Korea
- Jeonju, South Korea
- Jinju, South Korea
- Pusan, South Korea
- Seongnam, South Korea
- Seoul, South Korea
- Suncheon, South Korea
- Wŏnju, South Korea
Compensation & support
A stipend or compensation may be offered.
Compensation likely.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 19 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Changwon, South Korea; Daegu, South Korea; Daejeon, South Korea; Gwangju, South Korea; Jeonju, South Korea; Jinju, South Korea and 5 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.